SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000920465-20-000162
Filing Date
2020-12-14
Accepted
2020-12-14 16:18:09
Documents
2
Period of Report
2020-12-10

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_160798067443413.html 4  
1 FORM 4 wf-form4_160798067443413.xml 4 4012
2 POA, LAURA JOHNSON a102407999_1xljpcxpowerofa.htm EX-24 3683
  Complete submission text file 0000920465-20-000162.txt   9210
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Issuer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O LA JOLLA PHARMACEUTICAL COMPANY LA JOLLA VILLAGE DRIVE, SUITE 1070 SAN DIEGO CA 92122
Business Address
Johnson Laura L. (Reporting) CIK: 0001589362 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36282 | Film No.: 201386361